Overview

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the ECG effects of 10, 40, and 80 mcg/hr buprenorphine delivered by BTDS alone, or by BTDS dosed with naltrexone, relative to placebo in healthy male and female subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Purdue Pharma LP

Treatments:

Buprenorphine
Fluoroquinolones
Moxifloxacin
Naltrexone
Norgestimate, ethinyl estradiol drug combination